As filed with the Securities and Exchange Commission on August 9, 2006.

Registration Statement No. 333-134710

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 5

to

Form S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

GNC Corporation

(Exact name of registrant as specified in its charter)

300 Sixth Avenue

Pittsburgh, Pennsylvania 15222

(412) 288-4600

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Mark L. Weintrub, Esq.

Senior Vice President, Chief Legal Officer, and Secretary

GNC Corporation

300 Sixth Avenue

Pittsburgh, Pennsylvania 15222

(412) 288-4600

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies of All Communications to:

     Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

     If the securities being registered on this Form are being offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.    o

     If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

     If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

     If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

     The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until this Registration Statement shall become effective on such date as the SEC, acting pursuant to Section 8(a), may determine.

Subject to Completion

Preliminary Prospectus dated August 9, 2006

PROSPECTUS

23,530,000 Shares

GNC Corporation

Common Stock

        This is GNC Corporation’s initial public offering of its common stock. We are selling 9,391,176 shares and 14,138,824 shares are being sold by our stockholders. We will not receive any proceeds from the sale of our common stock by the selling stockholders.

      No public market currently exists for our common stock. We have applied to list our common stock on the New York Stock Exchange under the symbol “GNC.” We anticipate that the initial public offering price of our common stock will be between $16.00 and $18.00 per share.

       Investing in our common stock involves risk. See “Risk Factors” beginning on page 12 of this prospectus.

      The selling stockholders have granted the underwriters a 30-day option to purchase up to 3,529,500 additional shares of common stock at the public offering price, less the underwriting discount, to cover overallotments, if any. We will not receive any proceeds from the exercise of the overallotment option.

      Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

      The shares will be ready for delivery on or about                     , 2006.

The date of this prospectus is                     , 2006

GNC WORLDWIDE RETAIL FOOTPRINT Over 5,800 locations worldwide

4,812 U.S. Locations Corporate: 2,529

Franchise: 1,123

Rite Aid: 1,160 Note: As of March 31, 2006.

137 Canadian Locations

873 International Franchise Locations 45 Countries

 

Why GNC?

 

Leading source of health and wellness products for 70 years

innovative & quality products

Dedicated & knowledgeable sales associates

High-margin, value-added products

 

TABLE OF CONTENTS

      Through and including                     , 2006 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

      You should rely only on the information contained in this prospectus, any free writing prospectus prepared by or on behalf of us, or information to which we have referred you; we have not authorized anyone to provide you with information that is different. This prospectus is not an offer to sell or a solicitation of an offer to buy shares in any jurisdiction where an offer or sale of shares would be unlawful. The information in this prospectus is complete and accurate only as of the date on the front cover regardless of the time of delivery of this prospectus or of any sale of shares.

	•	introduced a single national pricing structure in order to improve our customer value perception;
	•	developed and executed a national, more diversified marketing program focused on reinforcing GNC’s brand name;
	•	overhauled our field organization and store programs to improve our customer shopping experience;
	•	focused our merchandising and marketing initiatives on driving increased traffic to our store locations;
	•	improved our supply chain and inventory management, resulting in better in-stock levels;

	•	reinvigorated our proprietary new product development activities;
	•	revitalized our vendor relationships, including their new product development activities and our exclusive or first-to-market access to new products;
	•	realigned our franchise system with our corporate strategies and re-acquired or closed unprofitable or non-compliant franchised stores;
	•	reduced our overhead cost structure; and
	•	launched www.gnc.com.

2005 Net Revenue by Segment		2005 Net Retail Revenue by Product Category

	(1)	Vitamins, minerals, and herbal and specialty supplements.

	•	net revenues of $382.8 million compared to $333.3 million for the same period in 2005;
	•	net cash provided by operating activities of $21.4 million compared to $(16.9) million for the same period in 2005;
	•	EBITDA of $40.4 million compared to $31.1 million for the same period in 2005;
	•	Adjusted EBITDA of $40.8 million compared to $31.5 million for the same period in 2005;
	•	net income of $13.1 million compared to $7.1 million for the same period in 2005;
	•	domestic company-owned same store sales of 11.5% compared to (5.2%) for the same period in 2005; and
	•	domestic franchised same store sales of 5.9% compared to (6.5%) for the same period in 2005.

	•	net revenues of $769.7 million compared to $669.8 million for the same period in 2005;
	•	net cash provided by operating activities of $33.9 million compared to $18.6 million for the same period in 2005;
	•	EBITDA of $77.9 million compared to $59.0 million for the same period in 2005;

	•	Adjusted EBITDA of $83.5 million compared to $59.8 million for the same period in 2005; and
	•	net income of $24.5 million compared to $9.8 million for the same period in 2005.

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2005				2006				2005				2006
		(Dollars in millions)
Net income		$	7.1			$	13.1			$	9.8			$	24.5
Interest expense, net			9.8				10.1				23.3				19.8
Income tax expense			4.1				7.7				5.6				14.5
Depreciation and amortization			10.1				9.5				20.3				19.1
EBITDA		$	31.1			$	40.4			$	59.0			$	77.9
Management fee payment			0.4				0.4				0.8				0.8
Discretionary payment to stock option holders			—				—				—				4.8
Adjusted EBITDA		$	31.5			$	40.8			$	59.8			$	83.5

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2005				2006				2005				2006
		(Dollars in millions)
Net cash provided by operating activities		$	(16.9	)		$	21.4			$	18.6			$	33.9
Cash paid for interest			11.0				11.5				13.2				20.1
Cash paid for taxes			2.4				10.7				2.7				10.9
Changes in assets and liabilities			34.6				(3.2	)			24.5				13.0
EBITDA		$	31.1			$	40.4			$	59.0			$	77.9
Management fee payment			0.4				0.4				0.8				0.8
Discretionary payment to stock option holders			—				—				—				4.8
Adjusted EBITDA		$	31.5			$	40.8			$	59.8			$	83.5

Total common stock offered		23,530,000 shares
Common stock offered by GNC      Corporation		9,391,176 shares
Common stock offered by the selling      stockholders		14,138,824 shares
Underwriters’ option to purchase      additional shares from the selling      stockholders in this offering		3,529,500 shares
Common stock outstanding after this      offering		59,955,124 shares
Voting rights		One vote per share
Use of proceeds		We estimate that the net proceeds to us from this offering will be approximately $147.8 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use our net proceeds to redeem all of our outstanding preferred stock, including the liquidation preference, additional redemption price, accumulated and unpaid dividends, and related expenses. A $1.00 change in the per share offering price would change net proceeds to us by approximately $8.8 million. Any remaining net proceeds will be used for working capital and general corporate purposes. We will not receive any proceeds from the sale of any shares by the selling stockholders. See “Use of Proceeds.”
Proposed New York Stock Exchange symbol		GNC
Risk factors		For a discussion of risks relating to our business and an investment in our common stock, see “Risk Factors” beginning on page 12.

	•	includes the shares of common stock to be issued by us upon the closing of this offering;
	•	assumes an initial public offering price of $17.00 per share, the midpoint of the range on the cover of this prospectus;
	•	excludes 4,795,766 shares of common stock subject to outstanding stock options with a weighted average exercise price of $3.67 per share; and
	•	excludes 3,800,000 shares of common stock available for future grant or issuance under our stock plans.

	•	gives effect to a 1.707-for-one split of shares of our common stock effected on July 27, 2006; and
	•	does not take into account the sale of up to 3,529,500 shares of our common stock that the underwriters have the option to purchase from the selling stockholders.

			Predecessor					Successor												Successor
			Period from																	Three				Three
			January 1,					27 Days												Months				Months
			2003 to					Ended				Year Ended				Year Ended				Ended				Ended
			December 4,					December 31,				December 31,				December 31,				March 31,				March 31,
			2003					2003				2004				2005				2005				2006
																				(Unaudited)
								(Dollars in millions)
Statement of Income Data:
Total revenues			$	1,340.2				$	89.3			$	1,344.7			$	1,317.7			$	336.4			$	386.9
Gross profit			$	405.3				$	25.7			$	449.5			$	419.0			$	106.0			$	130.0
Operating (loss) income			$	(638.3	)			$	3.4			$	100.7			$	72.2			$	17.8			$	27.9
Interest expense, net			$	121.1				$	2.8			$	34.5			$	43.1			$	13.5			$	9.7
Net (loss) income			$	(584.9	)			$	0.4			$	41.7			$	18.4			$	2.7			$	11.4
Other Data:
Net cash provided by operating activities			$	92.9				$	4.7			$	83.5			$	64.2			$	35.5			$	12.5
Net cash used in investing activities			$	(31.5	)			$	(740.0	)		$	(27.0	)		$	(21.5	)		$	(4.9	)		$	(3.8	)
Net cash (used in) provided by financing activities			$	(90.8	)			$	759.2			$	(4.5	)		$	(41.7	)		$	(37.9	)		$	(50.4	)
EBITDA(1)			$	(579.2	)			$	5.7			$	139.5			$	113.2			$	27.9			$	37.5
Adjusted EBITDA(1)			$	(579.2	)			$	5.7			$	141.0			$	114.7			$	28.2			$	42.6
Capital expenditures(2)			$	31.0				$	1.8			$	28.3			$	20.8			$	4.4			$	3.7
Number of stores (at end of period):
	Company-owned stores(3)			2,757					2,748				2,642				2,650				2,644				2,661
	Franchised stores(3)			1,978					2,009				2,036				2,014				2,034				1,996
	Store-within-a-store locations(3)			988					988				1,027				1,149				1,043				1,160
Same store sales growth:(4)
	Domestic company-owned			(0.4	)%				—				(4.1	)%			(1.5	)%			(7.8	)%			14.5	%
	Domestic franchised			(0.6	)%				—				(5.5	)%			(5.4	)%			(9.0	)%			6.8	%

																		As of March 31, 2006
																						As
																		Actual				Adjusted(5)
																		(Unaudited)
																		(Dollars in millions)
Balance Sheet Data:
Cash and cash equivalents																		$	44.3			$	25.2
Working capital(6)																			265.0				249.9
Total assets																			1,022.2				1,003.1
Total current and non-current long-term debt																			472.8				472.8
Cumulative redeemable exchangeable preferred stock																			131.0				—
Total stockholders’ equity																			169.7				285.6

(1)

We define EBITDA as net income (loss) before interest expense (net), income tax (benefit) expense, depreciation, and amortization. Management uses EBITDA as a tool to measure operating performance of the business. We use EBITDA as one criterion for evaluating our performance relative to our competitors and also as a measurement for the calculation of management incentive compensation. Although we primarily view EBITDA as an operating performance measure, we also consider it to be a useful analytical tool for measuring our liquidity, our leverage capacity, and our ability to service our debt and generate cash for other purposes. We also use EBITDA to determine our compliance with certain covenants in the senior credit facility, and the indentures governing the senior notes and senior subordinated notes, of our wholly owned subsidiary and operating company, General Nutrition Centers, Inc., or Centers. The reconciliation of EBITDA as presented below is different than that used for purposes of the covenants under the indentures governing the senior notes and senior subordinated notes. Historically, we have highlighted our use of EBITDA as a liquidity measure and for related purposes because of our focus on the holders of Centers’ debt. At the same time, however, management has also internally used EBITDA as a performance measure. EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income, operating income, or any other performance measures derived in accordance with GAAP, or as an alternative to GAAP cash flow from operating activities, as a measure of our profitability or liquidity. Some of the limitations of EBITDA are as follows:

	•	EBITDA does not reflect interest expense or the cash requirement necessary to service interest or principal payments on our debt;
	•	although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements; and
	•	although EBITDA is frequently used by securities analysts, lenders, and others in their evaluation of companies, our calculation of EBITDA may differ from other similarly titled measures of other companies, limiting its usefulness as a comparative measure.

	We compensate for these limitations by relying primarily on our GAAP results and using EBITDA only supplementally. See our consolidated financial statements included in this prospectus.
	Adjusted EBITDA is presented as additional information, as management also uses Adjusted EBITDA to evaluate the operating performance of the business and as a measurement for the calculation of management incentive compensation. Management believes that Adjusted EBITDA is commonly used by security analysts, lenders, and others. Adjusted EBITDA may not be comparable to other similarly titled measures reported by other companies, limiting its usefulness as a comparative measure.
	The following table reconciles EBITDA and Adjusted EBITDA to net (loss) income as determined in accordance with GAAP for the periods indicated:

		Predecessor					Successor												Successor
		Period from
		January 1,					27 Days												Three Months				Three Months
		2003 to					Ended				Year Ended				Year Ended				Ended				Ended
		December 4,					December 31,				December 31,				December 31,				March 31,				March 31,
		2003					2003				2004				2005				2005				2006
																			(Unaudited)
							(Dollars in millions)
Net (loss) income		$	(584.9	)			$	0.4			$	41.7			$	18.4			$	2.7			$	11.4
Interest expense, net			121.1					2.8				34.5				43.1				13.5				9.7
Income tax (benefit) expense			(174.5	)				0.2				24.5				10.7				1.6				6.8
Depreciation and amortization			59.1					2.3				38.8				41.0				10.1				9.6
EBITDA		$	(579.2	)			$	5.7			$	139.5			$	113.2			$	27.9			$	37.5
Management fee payment(a)			—					—				1.5				1.5				0.4				0.4
Discretionary payment to stock option holders(b)			—					—				—				—				—				4.8
Adjusted EBITDA		$	(579.2	)			$	5.7			$	141.0			$	114.7			$	28.2			$	42.6

	The following table reconciles EBITDA and Adjusted EBITDA to cash from operating activities as determined in accordance with GAAP for the periods indicated:

		Predecessor				Successor												Successor
		Period from
		January 1,				27 Days												Three Months				Three Months
		2003 to				Ended				Year Ended				Year Ended				Ended				Ended
		December 4,				December 31,				December 31,				December 31,				March 31,				March 31,
		2003				2003				2004				2005				2005				2006
																		(Unaudited)
						(Dollars in millions)
Net cash provided by operating activities		$	92.9			$	4.7			$	83.5			$	64.2			$	35.5			$	12.5
Cash paid for interest (excluding deferred financing fees)			122.5				0.7				32.7				32.7				2.2				8.6
Cash paid for taxes			2.5				—				5.1				2.9				0.3				0.2
(Decrease) increase in accounts receivable			(59.9	)			(2.9	)			(5.3	)			4.4				0.3				7.4
(Decrease) increase in inventory			(29.0	)			(3.8	)			15.1				23.9				20.9				41.3
Decrease (increase) in accounts payable			3.3				5.3				(3.9	)			2.9				(26.2	)			(25.8	)
Increase (decrease) in other assets			4.1				9.7				(16.6	)			(12.1	)			(6.7	)			(2.4	)
(Increase) decrease in other liabilities			(6.2	)			(8.0	)			28.9				(5.7	)			1.6				(4.3	)
Impairment of goodwill and intangible assets			(709.4	)			—				—				—				—				—
EBITDA		$	(579.2	)		$	5.7			$	139.5			$	113.2			$	27.9			$	37.5
Management fee payment(a)			—				—				1.5				1.5				0.4				0.4
Discretionary payment to stock option holders(b)			—				—				—				—				—				4.8
Adjusted EBITDA		$	(579.2	)		$	5.7			$	141.0			$	114.7			$	28.2			$	42.6

	(a)	The management fee represents an annual payment of $1.5 million to an affiliate of our principal stockholder and will not be payable subsequent to this offering.

	(b)	The discretionary payment to stock option holders was made in conjunction with the $49.9 million restricted payments made to our common stockholders in March 2006. It was recommended to and approved by our board of directors. Our board of directors decided to make the discretionary payment because it recognized that the restricted payments decreased the value of equity interest of option holders, who were not entitled to receive the restricted payments based upon their options. See “Dividend Policy.” Our board also wanted to recognize the option holders for their contribution to GNC in 2005.

(2)	For the full year ended December 31, 2003, capital expenditures were $32.8 million.

(3)	The following table summarizes our locations for the periods indicated:

			Predecessor					Successor												Successor
			Period from
			January 1,					27 Days												Three Months				Three Months
			2003 to					Ended				Year Ended				Year Ended				Ended				Ended
			December 4,					December 31,				December 31,				December 31,				March 31,				March 31,
			2003					2003				2004				2005				2005				2006
Company-owned Stores
Beginning of period				2,898					2,757				2,748				2,642				2,642				2,650
Store openings(a)				80					4				82				137				32				40
Store closings				(221	)				(13	)			(188	)			(129	)			(30	)			(29	)
End of period				2,757					2,748				2,642				2,650				2,644				2,661
Franchised stores
	Domestic
Beginning of period				1,352					1,352				1,355				1,290				1,290				1,156
Store openings				98					5				31				17				3				2
Store closings				(98	)				(2	)			(96	)			(151	)			(32	)			(35	)
End of period				1,352					1,355				1,290				1,156				1,261				1,123
	International
Beginning of period				557					626				654				746				746				858
Store openings				88					28				115				132				34				48
Store closings				(19	)				—				(23	)			(20	)			(7	)			(33	)
End of period				626					654				746				858				773				873
Store-within-a-Store Locations
Beginning of period				900					988				988				1,027				1,027				1,149
Location openings				93					—				44				130				17				11
Location closings				(5	)				—				(5	)			(8	)			(1	)			—
End of period				988					988				1,027				1,149				1,043				1,160
Total locations				5,723					5,745				5,705				5,813				5,721				5,817

	(a)	Includes re-acquired franchised stores.

(4)

Same store sales growth reflects the percentage change in same store sales in the period presented compared to the prior year period. Same store sales are calculated on a daily basis for each store and exclude the net sales of a store for any period if the store was not open during the same period of the prior year. Beginning in the first quarter of 2006, we also included our internet sales, as generated through www.gnc.com and drugstore.com, in our domestic company-owned same store sales calculation. When a store’s square footage has been changed as a result of reconfiguration or relocation in the same mall or shopping center, the store continues to be treated as a same store. If, during the period presented, a store was closed, relocated to a different mall or shopping center, or converted to a franchised store or a company-owned store, sales from that store up to and including the closing day or the day immediately preceding the relocation or conversion are included as same store sales as long as the store was open during the same period of the prior year. We exclude from the calculation sales during the period presented from the date of relocation to a different mall or shopping center and from the date of a conversion. In the second quarter of 2006, we modified the calculation method for domestic franchised same store sales consistent with this description, which has been the method historically used for domestic company-owned same store sales. Prior to the second quarter of 2006, we had included in domestic franchised same store sales the sales from franchised stores after relocation to a different mall or shopping center and from former company-

	owned stores after conversion to franchised stores. The franchised same store sales growth percentages for all prior periods have been adjusted to be consistent with the modified calculation method.
(5)	Adjusted to reflect (a) the sale by us of 9,391,176 shares of our common stock offered hereby at an assumed initial public offering price of $17.00 per share and the application of the estimated net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and (b) the payment after completion of the offering and the redemption of our Series A preferred stock with cash on hand of a dividend totaling $25.0 million to our common stockholders of record before the offering and discretionary payments to each of our employee and non-employee option holders immediately before the offering totaling $2.4 million. See “Use of Proceeds,” “Dividend Policy,” and “Capitalization.”
(6)	Working capital represents current assets less current liabilities.

RISK FACTORS

      Before deciding to invest in our common stock, you should carefully consider each of the following risk factors and all of the other information in this prospectus. The following risks comprise all the material risks of which we are aware; however, these risks and uncertainties may not be the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also adversely affect our business or financial performance. The following risks could materially harm our business, financial condition, future results, and cash flow. If that occurs, the trading price of our common stock could decline, and you could lose all or part of your investment.

Risks Relating to Our Business and Industry

      The U.S. nutritional supplements retail industry is large and highly fragmented. Participants include specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, on-line merchants, mail-order companies, and a variety of other smaller participants. We believe that the market is also highly sensitive to the introduction of new products, including various prescription drugs, which may rapidly capture a significant share of the market. In the United States, we also compete for sales with heavily advertised national brands manufactured by large pharmaceutical and food companies, as well as other retailers. In addition, as some products become more mainstream, we experience increased competition for those products as more participants enter the market. For example, when the trend in favor of low-carbohydrate products developed, we experienced increased competition for our diet products from supermarkets, drug stores, mass merchants, and other food companies, which adversely affected sales of our diet products. Our international competitors include large international pharmacy chains, major international supermarket chains, and other large U.S.-based companies with international operations. Our wholesale and manufacturing operations compete with other wholesalers and manufacturers of third-party nutritional supplements. We may not be able to compete effectively and our attempt to do so may require us to reduce our prices, which may result in lower margins. Failure to effectively compete could adversely affect our market share, revenues, and growth prospects.

      We are highly dependent upon consumer perception of the safety and quality of our products, as well as similar products distributed by other companies. Consumer perception of products can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our particular products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by our consumers as less favorable or that questions earlier research or publicity could have a material adverse effect on our ability to generate revenues. For example, sales of some of our VMHS products, such as St. John’s Wort, Sam-e, and Melatonin, and more recently sales of Vitamin E, were initially strong, but we believe decreased substantially as a result of negative publicity. As a result of the above factors, our operations may fluctuate significantly from quarter to quarter, which may impair our ability to make payments when due on our debt. Period-to-period comparisons of our results should not be relied upon as a measure of our future performance. Adverse publicity in the form of published scientific research or otherwise, whether or not accurate, that associates consumption of our products or any other similar products with illness or other adverse effects, that questions the benefits of our or similar products, or that claims that such products are ineffective could have a material adverse effect on our reputation, the demand for our products, and our ability to generate revenues.

      Our business is particularly subject to changing consumer trends and preferences, especially with respect to our diet products. For example, the recent trend in favor of low-carbohydrate diets was not as dependent on diet products as many other dietary programs, which caused and may continue to cause a significant reduction in sales in our diet category. Our continued success depends in part on our ability to anticipate and respond to these changes, and we may not be able to respond in a timely or commercially appropriate manner to these changes. If we are unable to do so, our customer relationships and product sales could be harmed significantly.

      Furthermore, the nutritional supplement industry is characterized by rapid and frequent changes in demand for products and new product introductions. Our failure to accurately predict these trends could negatively impact consumer opinion of our stores as a source for the latest products. This could harm our customer relationships and cause losses to our market share. The success of our new product offerings depends upon a number of factors, including our ability to:

      If we do not introduce new products or make enhancements to meet the changing needs of our customers in a timely manner, some of our products could become obsolete, which could have a material adverse effect on our revenues and operating results.

      In the last two years, we have experienced significant management changes. In December 2004, our then Chief Executive Officer resigned. In 2005, six of our then executive officers resigned at different times, including our former Chief Executive Officer, who served in that position for approximately five months. In November 2005, our board of directors appointed Joseph Fortunato, then our Chief Operating Officer, as our Chief Executive Officer. Some of these changes were the result of the officer’s personal decision to pursue other opportunities. The remaining changes were instituted by us as part of strategic initiatives executed in 2005 in order to enhance our business and reposition our operations for stronger future performance. Effective April 17, 2006, our Chief Operating Officer resigned to become a senior officer of Linens ‘n Things, Inc., which is controlled by an affiliate of Apollo Management, L.P., an affiliate of our principal stockholder. He continues to serve as Merchandising Counselor. At that time, we appointed a new Chief Merchandising Officer, who resigned effective April 28, 2006, because of disagreements about the direction of our merchandising efforts. We will continue to enhance our management team as necessary to strengthen our business for future growth. Although we do not anticipate additional significant management changes, these and other changes in management could result in changes to, or impact the execution of, our business strategy. Any such changes could be significant and could have a negative impact on our performance and results of operations. In addition, if we are unable to successfully transition members of management into their new positions, management resources could be constrained.

      The processing, formulation, manufacturing, packaging, labeling, advertising, and distribution of our products are subject to federal laws and regulation by one or more federal agencies, including the Food and Drug Administration, or FDA, the Federal Trade Commission, or FTC, the Consumer Product Safety Commission, the United States Department of Agriculture, and the Environmental Protection Agency. These activities are also regulated by various state, local, and international laws and agencies of the states and localities in which our products are sold. Government regulations may prevent or delay the introduction, or require the reformulation, of our products, which could result in lost revenues and increased costs to us. For instance, the FDA regulates, among other things, the composition, safety, labeling, and marketing of dietary supplements (including vitamins, minerals, herbs, and other dietary ingredients for human use). The FDA may not accept the evidence of safety for any new dietary ingredient that we may wish to market, may determine that a particular dietary supplement or ingredient presents an unacceptable health risk, and may determine that a particular claim or statement of nutritional value that we use to support the marketing of a dietary supplement is an impermissible drug claim or an unauthorized version of a “health claim.” See “Business — Government Regulations — Product Regulation.” Any of these actions could prevent us from marketing particular dietary supplement products or making certain claims or statements of nutritional support for them. The FDA could also require us to remove a particular product from the market. For example, in April 2004, the FDA banned the sale of products containing ephedra. Sale of products containing ephedra amounted to approximately $35.2 million, or 3.3%, of our retail sales in 2003 and approximately $182.9 million, or 17.1%, of our retail sales in 2002. Any future recall or removal would result in additional costs to us, including lost revenues from any additional products that we are required to remove from the market, any of which could be material. Any product recalls or removals could also lead to liability, substantial costs, and reduced growth prospects.

      Additional or more stringent regulations of dietary supplements and other products have been considered from time to time. These developments could require reformulation of some products to meet new standards, recalls or discontinuance of some products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of some products, additional or different labeling, additional scientific substantiation, adverse event reporting, or other new requirements. Any of these developments could increase our costs significantly. For example, legislation has been introduced in Congress to impose substantial new regulatory requirements for dietary supplements including adverse event reporting and other requirements. Key members of Congress and the dietary supplement industry have indicated that they have reached an agreement to support legislation requiring adverse event reporting. If enacted, new legislation could raise our costs and negatively impact our business. In addition, we expect that the FDA will soon adopt the proposed rules on Good Manufacturing Practice in manufacturing, packaging, or holding dietary ingredients and dietary supplements, which will apply to the products we manufacture. We may not be able to comply with the new rules without incurring additional expenses, which could be significant. See “Business — Government Regulation — Product Regulation” for additional information.

      The FTC exercises jurisdiction over the advertising of dietary supplements and has instituted numerous enforcement actions against dietary supplement companies, including us, for failure to have adequate substantiation for claims made in advertising or for the use of false or misleading advertising claims. As a result of these enforcement actions, we are currently subject to three consent decrees that limit our ability to make certain claims with respect to our products and required us to pay civil penalties and other amounts in the aggregate amount of $3.0 million. See “Business — Government Regulation — Product Regulation.” Failure by us or our franchisees to comply with the consent decrees and applicable regulations could occur from time to time. Violations of these orders could result in substantial monetary penalties, which could have a material adverse effect on our financial condition or results of operations.

      Our manufacturing operations produced approximately 33% of the products we sold for the first quarter of 2006 and approximately 35% for 2005. Other than powders and liquids, nearly all of our proprietary products are produced in our manufacturing facility located in Greenville, South Carolina. As of March 31, 2006, no one vendor supplied more than 10% of our raw materials. In the event any of our third-party suppliers or vendors were to become unable or unwilling to continue to provide raw materials in the required volumes and quality levels or in a timely manner, we would be required to identify and obtain acceptable replacement supply sources. If we are unable to obtain alternative supply sources, our business could be adversely affected. Any significant disruption in our operations at our Greenville, South Carolina facility for any reason, including regulatory requirements and loss of certifications, power interruptions, fires, hurricanes, war, or other force majeure, could disrupt our supply of products, adversely affecting our sales and customer relationships.

      We have invested significant resources to promote our GNC brand name in order to obtain the public recognition that we have today. However, we may be unable or unwilling to strictly enforce our trademark in each jurisdiction in which we do business. In addition, because of the differences in foreign trademark laws concerning proprietary rights, our trademark may not receive the same degree of protection in foreign countries as it does in the United States. Also, we may not always be able to successfully enforce our trademark against competitors or against challenges by others. For example, a third party is currently challenging our right to register in the United States certain marks that incorporate our “GNC Live Well” trademark. Our failure to successfully protect our trademark could diminish the value and effectiveness of our past and future marketing efforts and could cause customer confusion. This could in turn adversely affect our revenues and profitability.

      We are currently and may in the future be subject to intellectual property litigation and infringement claims, which could cause us to incur significant expenses or prevent us from manufacturing, selling, or using some aspect of our products. Claims of intellectual property infringement also may require us to enter into costly royalty or license agreements. However, we may be unable to obtain royalty or license agreements on terms acceptable to us or at all. Claims that our technology or products infringe on intellectual property rights could be costly and would divert the attention of management and key personnel, which in turn could adversely affect our revenues and profitability. We are currently subject to intellectual property infringement claims pursuant to litigation instituted against one of our wholly owned subsidiaries by a third party based on alleged infringement of patents by our subsidiary. We believe that these claims are without merit, and we intend to defend them vigorously. See “Business — Legal Proceedings.”

      As of March 31, 2006 approximately 34%, and as of December 31, 2005 approximately 35%, of our retail locations were operated by franchisees. Our franchise operations generated approximately 16% of our revenues for the first quarter of 2006 and for 2005. Our revenues from franchised stores depend on the franchisees’ ability to operate their stores profitably and adhere to our franchise standards. The closing of unprofitable franchised stores or the failure of franchisees to comply with our policies could adversely

affect our reputation and could reduce the amount of our franchise revenues. These factors could have a material adverse effect on our revenues and operating income.

      If we are unable to attract new franchisees or to convince existing franchisees to open additional stores, any growth in royalties from franchised stores will depend solely upon increases in revenues at existing franchised stores, which could be minimal. In addition, our ability to open additional franchised locations is limited by the territorial restrictions in our existing franchise agreements as well as our ability to identify additional markets in the United States and other countries that are not currently saturated with the products we offer. If we are unable to open additional franchised locations, we will have to sustain additional growth internally by attracting new and repeat customers to our existing locations.

      As of March 31, 2006, we had 873 international franchised stores in 45 international markets. We derived 7.9% of our revenues for the first quarter of 2006 and 8.2% of our revenues for 2005 from our international operations. As part of our business strategy, we intend to expand our international franchise presence. Our international operations are subject to a number of risks inherent to operating in foreign countries, and any expansion of our international operations will increase the effects of these risks. These risks include, among others:

      Any of these risks could have a material adverse effect on our international operations and our growth strategy.

      As a franchisor, we are subject to federal, state, and international laws regulating the offer and sale of franchises. These laws impose registration and extensive disclosure requirements on the offer and sale of franchises and frequently apply substantive standards to the relationship between franchisor and franchisee and limit the ability of a franchisor to terminate or refuse to renew a franchise. We may, therefore, be required to retain an under-performing franchise and may be unable to replace the franchisee, which could adversely impact franchise revenues. In addition, we cannot predict the nature and effect of any future legislation or regulation on our franchise operations.

      As a retailer, distributor, and manufacturer of products designed for human consumption, we are subject to product liability claims if the use of our products is alleged to have resulted in injury. Our products consist of vitamins, minerals, herbs, and other ingredients that are classified as foods or dietary supplements and are not subject to pre-market regulatory approval in the United States. Our products could contain contaminated substances, and some of our products contain ingredients that do not have long histories of human consumption. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur. In addition, third-party manufacturers produce many of the products we sell. As a distributor of products manufactured by third parties, we may also be liable for various product liability claims for products we do not manufacture. We have been and may be subject to various product liability claims, including, among others, that our products include inadequate instructions for use or inadequate warnings concerning possible side effects and interactions with other substances. For example, as of March 31, 2006, we have been named as a defendant in 227 pending cases involving the sale of products that contain ephedra. See “Business — Legal Proceedings.” Any product liability claim against us could result in increased costs and could adversely affect our reputation with our customers, which in turn could adversely affect our revenues and operating income. All claims to date have been tendered to the third-party manufacturer or to our insurer, and we have incurred no expense to date with respect to litigation involving ephedra products. Furthermore, we are entitled to indemnification by Numico for losses arising from claims related to products containing ephedra sold before December 5, 2003. All of the pending cases relate to products sold before that time.

      We have procured insurance independently for the following areas: (1) general liability; (2) product liability; (3) directors and officers liability; (4) property insurance; (5) workers’ compensation insurance; and (6) various other areas. We are self-insured for other areas, including: (1) medical benefits; (2) workers’ compensation coverage in New York, with a stop loss of $250,000; (3) physical damage to our tractors, trailers, and fleet vehicles for field personnel use; and (4) physical damages that may occur at company-owned stores. We are not insured for some property and casualty risks due to the frequency and severity of a loss, the cost of insurance, and the overall risk analysis. In addition, we carry product liability insurance coverage that requires us to pay deductibles/retentions with primary and excess liability coverage above the deductible/retention amount. Because of our deductibles and self-insured retention amounts, we have significant exposure to fluctuations in the number and severity of claims. We currently maintain product liability insurance with a retention of $1.0 million per claim with an aggregate cap on retained loss of $10.0 million. As a result, our insurance and claims expense could increase in the future. Alternatively, we could raise our deductibles/retentions, which would increase our already significant exposure to expense from claims. If any claim exceeds our coverage, we would bear the excess expense, in addition to our other self-insured amounts. If the frequency or severity of claims or our expenses increase, our operating income and profitability could be materially adversely affected. See “Business — Legal Proceedings.”

Risks Related to Our Substantial Debt

      As of March 31, 2006, our total debt was approximately $472.8 million, and we had an additional $65.1 million available for borrowing on a secured basis under our $75.0 million senior revolving credit facility after giving effect to the use of $9.9 million of the revolving credit facility to secure letters of credit. All of the debt under our senior credit facility bears interest at variable rates. We are subject to additional interest expense if these rates increase significantly, which could also reduce our ability to borrow additional funds.

      Our substantial debt could have important consequences on our financial condition. For example, it could:

      For additional information regarding the interest rates and maturity dates of our debt, see “Description of Certain Debt.”

      We may be unable to generate sufficient cash flow from operations, to realize anticipated cost savings and operating improvements on schedule or at all, or to obtain future borrowings under our credit facilities or otherwise in an amount sufficient to enable us to pay our debt or to fund our other liquidity needs. In addition, because we conduct our operations through our operating subsidiaries, we depend on those entities for dividends and other payments to generate the funds necessary to meet our financial obligations, including payments on our debt. Under certain circumstances, legal and contractual restrictions, as well as the financial condition and operating requirements of our subsidiaries, may limit our ability to obtain cash from our subsidiaries. If we do not have sufficient liquidity, we may need to refinance or restructure all or a portion of our debt on or before maturity, sell assets, or borrow more money. We may not be able to do so on terms satisfactory to us or at all.

      If we are unable to meet our obligations with respect to our debt, we could be forced to restructure or refinance our debt, seek equity financing, or sell assets. If we are unable to restructure, refinance, or sell assets in a timely manner or on terms satisfactory to us, we may default under our obligations. As of March 31, 2006, substantially all of our debt was subject to acceleration clauses. A default on any of our debt obligations could trigger these acceleration clauses and cause those and our other obligations to become immediately due and payable. Upon an acceleration of any of our debt, we may not be able to make payments under our debt.

      We are required by our senior credit facility to maintain certain financial ratios, including, but not limited to, fixed charge coverage and maximum total leverage ratios. Our ability to comply with these covenants and other provisions of the senior credit facility, the indentures governing Centers’ existing senior notes and senior subordinated notes, or similar covenants in future debt financings may be affected by changes in our operating and financial performance, changes in general business and economic conditions, adverse regulatory developments, or other events beyond our control. The breach of any of these covenants could result in a default under our debt, which could cause those and other obligations to become immediately due and payable. If any of our debt is accelerated, we may not be able to repay it.

      We and our subsidiaries may be able to incur substantial additional debt in the future, including secured debt. Although our senior credit facility and the indentures governing Centers’ existing senior notes and senior subordinated notes contain restrictions on the incurrence of additional debt, these restrictions are subject to a number of qualifications and exceptions, and under certain circumstances, debt incurred in compliance with these restrictions could be substantial. If additional debt is added to our current level of debt, the substantial risks described above would increase.

Risks Relating to an Investment in Our Stock

      Immediately following this offering, 58.3% of our common stock, or 52.4% if the underwriters exercise their overallotment option in full, will be held by GNC Investors, LLC, our principal stockholder. In our stockholders’ agreement, each of our current stockholders, including our principal stockholder, has irrevocably appointed Apollo Investment Fund V, L.P., an affiliate of our principal stockholder, as its proxy and attorney-in-fact to vote all of the shares of common stock held by the stockholder at any time for all matters subject to the vote of the stockholder in the manner determined by Apollo Investment Fund V in its sole and absolute discretion, whether at any meeting of the stockholders or by written consent or otherwise. The proxy remains in effect for so long as Apollo Investment Fund V, together with related co-investment entities (which we refer to along with Apollo Investment Fund V as Apollo Funds V), which include our principal stockholder in certain circumstances, own at least 3,584,700 shares of our common stock. Accordingly, upon completion of this offering and giving effect to the use of proceeds from the offering, Apollo Investment Fund V will have the right to vote shares representing 60.8% of our common stock, or 54.9% if the underwriters exercise their overallotment option in full. In addition, so long as Apollo Funds V own at least 3,584,700 shares of our common stock, and subject to the rights of the holders of our preferred stock, Apollo Investment Fund V has the right to nominate all of the members of our board of directors, and each of our current stockholders has agreed to vote all shares of common stock held by the stockholder to ensure the election of the directors nominated by Apollo Investment Fund V. As a result, Apollo Investment Fund V will continue to be able to exercise control over all matters requiring stockholder approval, including the election of directors, amendment of our certificate of incorporation, and approval of significant corporate transactions, and it will have significant control over our management and policies. This control may have the effect of delaying or preventing changes in control or changes in management, or limiting the ability of our other stockholders to approve transactions that they may deem to be in their best interest. See “Description of Capital Stock — Stockholders’ Agreement.”

      After the completion of this offering, GNC Investors, LLC will own more than 50% of our outstanding common stock, and Apollo Investment Fund V will hold more than 50% of the total voting power of our common stock, and, therefore, we will be a “controlled company” under the NYSE corporate governance standards. As a controlled company, we intend to utilize certain exemptions under the NYSE standards that free us from the obligation to comply with certain NYSE corporate governance requirements, including the requirements:

      As a result of our use of the controlled company exemptions, you will not have the same protection afforded to stockholders of companies that are subject to all of the NYSE corporate governance requirements. See “Management — Board Composition” for more information.

      The initial public offering price for the shares of our common stock sold in this offering will be determined by negotiation between the representatives of the underwriters, Apollo Management V, L.P., and us. This price may not reflect the market price of our common stock following this offering. In addition, the market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:

      In addition, the stock market in general, the New York Stock Exchange, and the market for health and nutritional supplements companies in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. If any of these factors causes us to fail to meet the expectations of securities analysts or investors, or if adverse conditions prevail or are perceived to prevail with respect to our business, the price of our common stock would likely drop significantly.

      We currently do not plan to declare dividends on shares of our common stock after the offering and for the foreseeable future. Further, Centers is currently restricted from declaring or paying cash dividends to us pursuant to the terms of its senior credit facility, its senior subordinated notes, and its senior notes, which effectively restricts us from declaring or paying any cash dividends. Centers has already used exceptions to these restrictions to make payments totaling $49.9 million to our common stockholders in March 2006. We have declared a dividend totaling $25.0 million to our common stockholders of record immediately before the offering, which will be payable by us with cash on hand after completion of the offering and the redemption of our Series A preferred stock. See “Dividend Policy” for more information.

Consequently, your only opportunity to achieve a return on your investment in our company will be if the market price of our common stock appreciates and you sell your shares at a profit. There is no guarantee that the price of our common stock that will prevail in the market after this offering will ever exceed the price that you pay.

      After this offering, we will have 59,955,124 shares of common stock outstanding. The 23,530,000 shares sold in this offering, or 27,059,500 shares if the underwriters’ overallotment option is exercised in full, will be freely tradable without restriction or further registration under federal securities laws unless purchased by our affiliates. The remaining shares of common stock outstanding after this offering will be available for sale in the public market as follows:

      The above table assumes the effectiveness of the lock-up agreements under which our executive officers, directors, and our principal stockholder have agreed not to sell or otherwise dispose of their shares of common stock and that we or the representatives of the underwriters have not waived the market stand-off provisions applicable to holders of options to purchase our common stock. Holders of options to purchase 4,795,766 shares of our common stock have entered into stock option agreements with us pursuant to which they have agreed not to sell or otherwise dispose of shares of common stock underlying these options for a period of 180 days after the date of this prospectus without the prior written consent of GNC or the underwriters subject to exceptions and possible extension as described in “Underwriting.”

      Merrill Lynch, Lehman Brothers Inc., and UBS Securities LLC may, in their discretion and at any time without notice, release all or any portion of the securities subject to the lock-up agreements or the market stand-off provisions in our stock option agreements.

      Sales of substantial amounts of our common stock in the public market following this offering, or the perception that these sales may occur, could cause the market price of our common stock to decline. After the lock-up agreements pertaining to this offering expire, additional stockholders, including our principal stockholder, will be able to sell their shares in the public market, subject to legal restrictions on transfer. As soon as practicable upon completion of this offering, we also intend to file registration statements covering shares of our common stock issued or reserved for issuance under our stock plans. In addition, under our stockholders’ agreement, some of our stockholders are entitled to registration rights. Subject to the terms of the lock-up agreements, registration of the sale of these shares of our common stock would generally permit their sale into the market immediately after registration. These registration rights of our stockholders could impair our ability to raise capital by depressing the price of our common stock. We may also sell additional shares of common stock in subsequent public offerings, which may adversely affect market prices for our common stock. See “Shares Eligible for Future Sale” for more information.

      The initial public offering price of our common stock will be considerably more than the net tangible book value per share of our outstanding common stock. Accordingly, investors purchasing shares of common stock from us in this offering will:

      To the extent outstanding stock options are exercised, there will be further dilution to new investors. See “Dilution” for more information.

      Certain provisions of our organizational documents and Delaware law could discourage potential acquisition proposals, delay or prevent a change in control of our company, or limit the price that investors may be willing to pay in the future for shares of our common stock. For example, our certificate of incorporation and by-laws permit us to issue, without any further vote or action by the stockholders, up to 150,000,000 shares of preferred stock in one or more series and, with respect to each series, to fix the number of shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional, and other special rights, if any, and any qualifications, limitations, or restrictions of the shares of the series. In addition, our certificate of incorporation permits our board of directors to adopt amendments to our by-laws. See “Description of Capital Stock — Provisions of Our Amended and Restated Certificate of Incorporation and Amended and Restated By-laws and Delaware Law that May Have an Anti-Takeover Effect.”

      We are a holding company and, accordingly, substantially all of our operations are conducted through our subsidiaries. Our subsidiaries are separate and distinct legal entities. As a result, our cash flow depends upon the earnings of our subsidiaries. In addition, we depend on the distribution of earnings, loans, or other payments by our subsidiaries to us. Our subsidiaries have no obligation to provide us with funds for our payment obligations. If there is an insolvency, liquidation, or other reorganization of any of our subsidiaries, our stockholders will have no right to proceed against their assets. Creditors of those subsidiaries will be entitled to payment in full from the sale or other disposal of the assets of those subsidiaries before we, as a stockholder, would be entitled to receive any distribution from that sale or disposal.

ABOUT THIS PROSPECTUS

      Throughout this prospectus, we use market data and industry forecasts and projections that we have obtained from market research, publicly available information, and industry publications. The industry forecasts and projections are based on industry surveys and the preparers’ experience in the industry, and we cannot give you any assurance that any of the projected results will be achieved.

      We own or have rights to trademarks or trade names that we use in conjunction with the operation of our business. Our service marks and trademarks include the GNC^® name. Each trademark, trade name, or service mark of any other company appearing in this prospectus belongs to its holder. Use or display by us of other parties’ trademarks, trade names, or service marks is not intended to and does not imply a relationship with, or endorsement or sponsorship by us of, the owner of the trademark, trade name, or service mark.

      The contents of our website, www.gnc.com, are not a part of this prospectus.

      We refer to the terms EBITDA and Adjusted EBITDA in various places in this prospectus. EBITDA and Adjusted EBITDA are non-GAAP measures of performance and liquidity, as applicable. For the definitions of EBITDA and Adjusted EBITDA and a reconciliation of net income and net cash provided by operating activities to EBITDA and EBITDA to Adjusted EBITDA, see note (1) to “Summary Consolidated Financial Data.”

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

      This prospectus includes forward-looking statements with respect to our financial condition, results of operations, and business that is not historical information. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, and other information that is not historical information. Many of these statements appear, in particular, under the headings “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Business.” Forward-looking statements can be identified by the use of terminology such as “subject to,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “can,” the negatives thereof, variations thereon, and similar expressions, or by discussions of strategy.

      All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. Factors that may materially affect such forward-looking statements include, among others:

      Consequently, forward-looking statements should be regarded solely as our current plans, estimates, and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance, or achievements. We do not undertake and specifically decline any obligation to update, republish, or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.

USE OF PROCEEDS

      We estimate that our net proceeds from this offering will be approximately $147.8 million, based on an assumed initial public offering price of $17.00 per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses. A $1.00 change in the per share offering price would change net proceeds to us by approximately $8.8 million. We will not receive any proceeds from the sale of the shares being offered by the selling stockholders.

      We intend to use our net proceeds to redeem all $100.0 million in liquidation preference of our outstanding Series A preferred stock at a redemption price per share of $1,085.71, plus accumulated dividends not paid in cash through the redemption date and related expenses. Any of our remaining net proceeds will be used for working capital and general corporate purposes.

      We issued the Series A preferred stock in December 2003 to our principal stockholder as part of its equity contribution in connection with the Numico acquisition. In the same month, our principal stockholder sold the shares of Series A preferred stock to qualified institutional buyers in a private offering pursuant to Rule 144A under the Securities Act. In September 2004, we exchanged the shares of Series A preferred stock for shares registered under the Securities Act. The shares are eligible for trading on the PORTAL^sm Market. We believe that none of the holders of the Series A preferred stock are our affiliates or affiliates of our principal stockholder. The holders of the Series A preferred stock are entitled to receive dividends at a rate per year equal to 12% of the liquidation preference of $1,000 per share plus accumulated dividends. Dividends on the Series A preferred stock are payable quarterly, but we have elected not to pay dividends in cash, and, as of June 1, 2006, the accumulated dividends for each share totaled $342.18.

      To the extent that the underwriters exercise their option to purchase additional shares of common stock to cover overallotments from the selling stockholders, we will not receive any proceeds from the exercise of this option.

DIVIDEND POLICY

      We currently do not anticipate paying any cash dividends after the offering and for the foreseeable future. Instead, we anticipate that all of our earnings on our common stock, in the foreseeable future will be used to repay debt, to provide working capital, to support our operations, and to finance the growth and development of our business. Any future determination relating to dividend policy will be made at the discretion of our board of directors and will depend on a number of factors, including restrictions in our debt instruments, our future earnings, capital requirements, financial condition, future prospects, and applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits.

      Centers is currently restricted from declaring or paying cash dividends to us pursuant to the terms of its senior credit facility, its senior subordinated notes, and its senior notes, which restricts our ability to declare or pay any cash dividends. Centers has already used exceptions to these restrictions to make permitted restricted payments totaling $49.9 million to our common stockholders in March 2006. These payments were determined to be in compliance with Centers’ debt covenants and the terms of our Series A preferred stock. We have declared a dividend totaling $25.0 million to our common stockholders of record before the offering who consist of our principal stockholder, some of our directors and executive officers, and other members of GNC management. See “Certain Relationships and Related Transactions — Planned Dividend and Discretionary Payments.” The dividend declaration is expressly conditioned upon the redemption of our outstanding Series A preferred stock. See “Use of Proceeds.” The dividend will be payable as a permitted restricted payment with cash on hand after completion of the offering and the redemption of our Series A preferred stock.

CAPITALIZATION

      The following table sets forth our capitalization as of June 30, 2006 on:

      The table below should be read in conjunction with “Use of Proceeds,” “Selected Consolidated Financial Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Description of Capital Stock,” “Description of Certain Debt,” and our consolidated financial statements and their notes included in this prospectus.

DILUTION

      At June 30, 2006, the net tangible book value of our common stock was approximately $(166.3) million, or approximately $(3.29) per share of our common stock. After giving effect to (1) the sale of shares of our common stock in this offering at an assumed initial public offering price of $17.00 per share, and after deducting estimated underwriting discounts and commissions and the estimated offering expenses of this offering, and (2) the payment after the offering and the redemption of our Series A preferred stock (including the redemption premium of $8.6 million) to our common stockholders of record before the offering of a dividend totaling $25.0 million and discretionary payments to each of our employee and non-employee option holders immediately before the offering totaling $2.4 million, the as adjusted net tangible book value at June 30, 2006 attributable to common stockholders would have been approximately $(50.4) million, or approximately $(0.84) per share of our common stock. This represents a net increase in net tangible book value of $2.45 per existing share and an immediate dilution in net tangible book value of $17.84 per share to new stockholders. The following table illustrates this per share dilution to new stockholders:

      A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share would decrease (increase) our as adjusted tangible deficit by approximately $8.8 million, the as adjusted net tangible book deficit per share after this offering by approximately $0.15 per share, and the dilution per share to new stockholders in this offering by approximately $0.85, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us.

      The table below summarizes, as of June 30, 2006, the differences for (1) our existing stockholders, (2) selling stockholders, and (3) investors in this offering, with respect to the number of shares of common stock purchased from us, the total consideration paid, and the average price per share paid before deducting fees and expenses.

      The foregoing discussion and tables assume no exercise of stock options to purchase 4,810,890 shares of our common stock subject to outstanding stock options with a weighted average exercise price of $3.64 per share as of June 30, 2006 and exclude 3,800,000 shares of our common stock available for future grant or issuance under our stock plans. To the extent that any options having an exercise price that is less than the offering price of this offering are exercised, new investors will experience further dilution.

UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL DATA

      The unaudited pro forma consolidated statements of operations for the year ended December 31, 2005 and for the six months ended June 30, 2006 give effect to this offering as if it had been consummated on January 1, 2005. The unaudited pro forma consolidated balance sheet as of June 30, 2006 gives effect to this offering as if it been consummated on such date. The unaudited pro forma consolidated financial statements give effect to: (1) the issuance of 9,391,176 shares of our common stock at an assumed offering price of $17.00 per share resulting in net proceeds of $147.8 million (after deducting estimated offering expenses of $11.8 million), (2) the redemption of our Series A preferred stock at a redemption price of $1,085.71, plus accumulated dividends, and (3) the payment after the completion of the offering and the redemption of our preferred stock of a $25.0 million dividend to our common stockholders and a $2.4 million discretionary payment at the same time to our employee and non-employee option holders, each to be funded with available cash on hand.

      The unaudited pro forma consolidated financial data do not purport to represent what our results of operations would have been if this offering had occurred as of the dates indicated, nor are they indicative of results for any future periods.

      The unaudited pro forma consolidated statements of operations do not present the effect of non-recurring charges resulting from the offering as a result of: (1) the redemption premium of $8.6 million related to the redemption of our Series A preferred stock and (2) discretionary payments after the offering and the preferred stock redemption to each of our employee and non-employee option holders immediately before the offering totaling $2.4 million.

      The unaudited pro forma consolidated financial data are presented for informational purposes only and should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our historical consolidated financial statements and accompanying notes included in this prospectus.

GNC CORPORATION AND SUBSIDIARIES

Unaudited Pro Forma Consolidated Statement of Operations

For the year ended December 31, 2005

GNC CORPORATION AND SUBSIDIARIES

Unaudited Pro Forma Consolidated Statement of Operations

For the six months ended June 30, 2006

GNC CORPORATION AND SUBSIDIARIES

Unaudited Pro Forma Consolidated Balance Sheet

As of June 30, 2006